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Overexpressiona b s t r a c t
Tetherin/BST-2/CD317 inhibits HIV-1 release from infected cells, but the viral Vpu protein efﬁciently
antagonizes this antiviral activity through direct interaction between the transmembrane (TM)
domains of each protein. Here, we demonstrated that overexpression of an inactive tetherin delGPI
mutant, the TM domain of which could competitively block Vpu targeting of endogenous tetherin,
potently inhibited HIV-1 release from human tetherin-positive cells in both transient and stable
expression conditions. These results also suggest that heterologous dimerization occurred between
the delGPI mutant and endogenous tetherin. These ﬁndings suggest that blocking the Vpu/tetherin
interface may be a novel therapeutic approach against HIV-1 release.
Structured summary of protein interactions:
Vpu and Tetherin colocalize by ﬂuorescence microscopy (View interaction)
Tetherin physically interacts with Vpu by anti tag coimmunoprecipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction residues [11,12], all of which contribute to the formation of cys-HIV-1 has overcome several human defense mechanisms for
efﬁcient infection. Thus, blocking viral accessory proteins to re-
store the antiviral function of host restriction factors is considered
a promising approach for HIV-1 treatment. Several recent studies
have reported effective inhibitors targeting the antagonistic func-
tion of HIV-1 Vif against the host protein APOBEC3G [1–3]. Similar
to the relationship between APOBEC3G and HIV-1 Vif, the antiviral
activity of human tetherin/BST-2/CD317 is counteracted by HIV-1
Vpu [4,5].
Tetherin, an IFN-inducible host restriction factor responsible for
the inhibition of HIV-1 release [4,5], contains a transmembrane
(TM) domain, a C-terminal glycosylphosphatidylinositol (GPI) an-
chor [6] and an ectodomain, forming a long rodlike coiled-coil
structure [7–10]. The tetherin ectodomain encodes three cysteineteine-linked dimers [13,14] and are critical for its antiviral activity
[15]. HIV-1 Vpu antagonizes tetherin through a protein–protein
interaction which maps to the TM domains of each protein
[16–19]. One potential approach to disrupting Vpu function is to
target the Vpu–tetherin interface with small molecules or a TM
peptide decoy that binds the Vpu membrane-spanning domain
and blocks its interactions with tetherin [20]. Although a nuclear
magnetic resonance (NMR) structure study has provided informa-
tion on the interface between the two proteins [21], the crystal
structure of the protein complex is not yet available, making the
rational design of inhibitors difﬁcult.
In this study, we demonstrated that a human tetherin delGPI
mutant retaining the TM domain potently inhibited the release of
wild-type HIV-1 in tetherin-positive HeLa cells in both transient
and stable expression conditions. However, the corresponding
tetherin delGPI mutant containing a replacement African green
monkey (AGM) tetherin TM domain showed no such activity, sug-
gesting that this truncated molecule could block and competitively
inhibit the Vpu interaction with endogenous tetherin at the cell
surface via its TM region. While this molecule also allowed a mod-
erately weak recovery in the release of virus without Vpu, the mu-
tant with changes at the C53,63,91A dimerization sites did not
show this activity, suggesting the occurrence of heterologous
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cules. These ﬁndings support the possibility of blocking the Vpu/
tetherin interface as a therapeutic approach.
2. Materials and methods
2.1. Plasmid construction
The human tetherin gene (Swiss-Prot entries Q10589) was sub-
cloned into the VR1012 vector for eukaryotic expression. The inter-
nally HA-tagged tetherin (inserted in the 30 end at codon 154) has
been reported elsewhere [14,16], and an N-terminally Flag-tagged
tetherin was also constructed as previously described [22]. The
tetherin mutant lacking the GPI anchor (delGPI) was generated
by replacing codon 161 with a termination codon. The human teth-
erin gene with the TM sequence replaced by the synthetic AGMTM
sequence (ShineGene, Shanghai, China) was constructed by
overlapping PCR as previously described [16]. The tetherin cys-
teine-to-alanine mutants were engineered using the QuickChange
mutagenesis system (Stratagene, Santa Clara, CA, USA). Fragments
encoding tetherin delGPI and the AGMTM delGPI mutant were
ampliﬁed by PCR and subcloned into an HIV-1-based lentiviral vec-
tor pLVX-Puro (Clontech, Mountain View, CA, USA) for stable
expression. VR1012 encoding codon-optimized HIV-1 NL4-3 Vpu
with a cmyc tag and the expression vector for C-terminally HA-
tagged human CD4 [19], as well as the HIV-1 proviral clones
pNL4-3 and pNL4-3 delVpu [23], were previously described.
2.2. Cells and transfections
HeLa (No. CCL-2) and HEK293T (No. CRL-11268) cells were pur-
chased from the American Tissue Culture Collection (ATCC, Manas-
sas, VA, USA), and the TZM-bl indicator cell line (Catalog No. 8129),
was obtained from the National Institutes of Health AIDS Research
and Reference Reagent Program (NIH-ARRRP, Germantown, MD,
USA). All cells were cultured in Dulbecco’s Modiﬁed Eagle’s Med-
ium (DMEM) supplemented with 10% fetal bovine serum (FBS) at
37 C/5% CO2. Transfections of HeLa and 293T cells were performed
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), accord-
ing to the manufacturer’s instructions.
2.3. Protein analysis
Cell lysates prepared with RIPA buffer were mixed with sodium
dodecyl sulfate (SDS) sample buffer and boiled for 10 min. The
samples were subjected to SDS–polyacrylamide gel electrophoresis
(PAGE) and transferred to a nitrocellulose membrane for Western
blotting. HA-tagged tetherin was detected with an anti-HA mono-
clonal antibody (mAb, Covance, Princeton, NJ, USA). Vpu-cmyc was
detected with an anti-myc mAb (Millipore, Billerica, MA, USA).
Pr55Gag and p24CA were detected with an anti-HIV capsid (p24)
mAb (Covance). Tubulin was detected with an anti-tubulin mAb
(Covance). Alkaline phosphatase (AP)-conjugated goat anti-mouse
and goat anti-rabbit IgG (Jackson Immunoresearch, West Grove,
PA, USA) were used as secondary antibodies. The p24CA band of
each virion sample was quantiﬁed by densitometry using
Photoshop CS2 (Adobe, San Jose, CA, USA). Before electrophoresis
of proteins in reducing/non-reducing conditions, samples were
treated with sample buffer with or without b-mercaptoethanol
(b-ME).
2.4. Immunoﬂuorescence microscopy
Evaluation of co-localization of tetherin and Vpu was performed
as follows: HeLa cells seeded on coverslips in a 24-well plate were
transfected with 200 ng of each plasmid. At 24 h post-transfection,cells were ﬁxed with 2% formaldehyde and permeabilized with
0.25% Triton X-100 (Sigma, St. Louis, MO, USA), blocked in 10%
FBS in PBS and incubated with a mixture of anti-myc mAb (Milli-
pore) and rabbit anti-HA polyclonal antibody (pAb, Covance) di-
luted 1:1000 for 1 h. Cells were then stained with a mixture of
AlexaFluor 488-conjugated goat anti-mouse IgG (Molecular Probes,
Invitrogen) and Rhodamine Red-X goat anti-rabbit IgG (Molecular
Probes) diluted 1:1000 for 1 h. After washing three times, the cov-
erslips were mounted on glass slides with mounting medium con-
taining DAPI (Invitrogen). The samples were observed and imaged
on a Zeiss LSM710 confocal microscope.
2.5. Co-immunoprecipitation
Transfected 293T cells were lysed for 30 min at 4 C in 500 ll ly-
sis buffer containing 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1%
Triton X-100 (Sigma), 1% CHAPS (Sigma) and a protease inhibitor
cocktail (Roche, Basel, Switzerland), followed by centrifugation at
10000g for 10 min at 4 C to pellet the cellular debris. Immuno-
precipitations were performed on the pre-cleared supernatants by
adding 30 ll HA beads rocking at 4 C for 4 h. After washing beads
ﬁve times with lysis buffer, the pellet was resuspended in 30 ll
glycine HCl pH 2.0 elution buffer. The eluted samples were sepa-
rated by SDS–PAGE and analyzed by Western blotting.
2.6. Virion production and infectivity assay
For transient transfection assays, HIV-1 particles were produced
in HeLa or 293T cells in a 6-well plate with 1 lg proviral constructs
and indicated amounts of other plasmids. For VSV-G pseudotyped
HIV-1 infection assays, 293T cells in a T-25 ﬂask were co-transfected
with 3 lg proviral constructs and 500 ng VSV-G plasmids. At 48 h
post-transfection, the supernatant was collected, ﬁltered and used
to infect 293T and HeLa cells in 6-well plates (0.8 ml/well). At 4 h
post-infection, cells were washed three times with fresh medium
and cultured for 48 h after replacement with 2 ml complete
medium. The culture medium of producer cells was clariﬁed with
a 0.22-lm ﬁlter, and virions were pelleted through a 20% sucrose
layer at 110000g for 1 h and resuspended in 30 ll RIPA buffer.
Virus particle pellets and corresponding cell lysates were analyzed
by Western blotting. In single-cycle infectivity assays, 50 ll of the
ﬁltered supernatant was mixed with DEAE-dextran (Sigma) at a
ﬁnal concentration of 15 lg/ml and incubated with TZM-bl
indicator cells in a 96-well plate. At 48 h post-infection, the cells
were lysed, mixed with luciferase substrates and assayed for lucif-
erase activity using a ﬂuorescence microplate reader to represent
released virion yield.
2.7. Stable delivery of delGPI tetherin
VSV-G pseudotyped lentiviral particles expressing tetherin mu-
tants were generated by co-transfection of 293T cells with HIV-1
packaging plasmids (RRE, Rev), VSV-G plasmid and the tetherin
mutant lentiviral vector. At 48 h post-transfection, the supernatant
containing the lentivirus was collected, ﬁltered and used to infect
293T and HeLa cells. Transduced cells were selected for two weeks
in complete medium supplemented with 5 lg/ml (293T) or 15 lg/
ml (HeLa) puromycin. Expression of stable delGPI tetherin was val-
idated by Western blot using an anti-HA mAb.
3. Results
3.1. Design of tetherin delGPI mutants and their putative activities
The TM domain of tetherin is responsible for Vpu binding, and
direct interaction between these molecules is necessary for the
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inactive tetherin containing the TM domain is still able to bind vir-
al Vpu and block its interaction with endogenous tetherin, it may
relieve the inhibitory activity against HIV-1. A previously reported
tetherin GPI-anchor deletion (delGPI) mutant can still be trans-
ported to the cell surface but is completely devoid of antiviral func-
tion [14]. Since that mutant still contains the intact TM domain, we
used it along with several other constructs as controls (Fig. 1A). A
human tetherin fusion protein, the TM domain of which has been
replaced by that of AGM tetherin, is completely insensitive to
Vpu [16]. Therefore, the tetherin AGMTM delGPI mutant was intro-
duced to conﬁrm that the potential block of the human delGPI
tetherin is mediated by its TM domain.
Three cysteines in the extracellular region (C53, C63 and C91)
are responsible for homologous dimerization [13,14]. We hypoth-
esized that if the tetherin delGPI mutant can still dimerize, it
may possibly interact with endogenous tetherin. If the heterodimer
is formed, it would be of interest to determine the antiviral activity
this non-membrane-bound molecule. To verify this hypothesis, we
introduced the C53,63,91A mutations into two constructs, tetherin
delGPI C-A and tetherin AGMTM delGPI C-A.
3.2. Tetherin delGPI mutant lacks antiviral function
The dysfunction of the tetherin delGPI mutant was validated
initially by co-transfecting 293T cells with the HIV-1 proviral plas-
mid (wild-type or delVpu) and tetherin plasmid (wild-type or del-
GPI). After 48 h, both virions and cells were analyzed by
immunoblotting. As shown in Fig. 1B, the release of Vpu-deﬁcient
HIV-1 was very low from cells expressing wild-type tetherin, com-
pared to that of wild-type HIV-1. However, equivalent amounts of
Vpu-deﬁcient and wild-type HIV-1 were released from cells
expressing the tetherin delGPI mutant. These results suggest that
the tetherin delGPI mutant had completely lost its antiviral
function.Fig. 1. Schematic representation and basic characteristics of tetherin delGPI mutational v
and their putative activities. Human TM domain (black zigzag), AGMTM domain (light g
Veriﬁcation of the antiviral activity of tetherin delGPI mutant. 293T cells were co-transfec
plasmid. The p24CA content of virions and intracellular Pr55Gag and tetherin in cells we
transfected with 500 ng of each tetherin mutant for 48 h. Cells were divided into two por
an HA antibody to detect tetherin. Monomers and dimers are indicated.3.3. Tetherin delGPI mutant retains dimerization capacity
Reducing/non-reducing conditions were used to detect the
aggregation state of tetherin delGPI mutants. Transfected 293T
cells were divided into two fractions; one was treated with sample
buffer containing b-ME, while the other was treated with sample
buffer without b-ME. As shown in Fig. 1C, the reduced samples in
the left four lanes show bands corresponding to monomers of
25 kDa. Among the non-reduced samples in the right four lanes,
tetherin delGPI and tetherin AGMTM delGPI migrated as 50 kDa
dimers, while the cysteine mutants, tetherin delGPI C-A and teth-
erin AGMTM delGPI C-A, showed mostly monomeric bands along
with a few dimerization bands. These results suggest that tetherin
delGPI could still dimerize, while this ability was signiﬁcantly im-
pacted by the C53,63,91A mutations.
3.4. Tetherin delGPI mutant partially co-localizes with HIV-1 Vpu
Vpu mainly localizes to the trans-Golgi network (TGN), but it is
also found in the endoplasmic reticulum (ER) and the recycling
endosome. Vpu and tetherin co-localize in the cytoplasm during
the process of tetherin glycosylation in the TGN and transport
through the ER and recycling endosomes to the cell surface where
it inhibits virus release [4,14,25]. Here, the subcellular localizations
of tetherin delGPI and Vpu were evaluated by a confocal immuno-
ﬂuorescence assay. As shown in Fig. 2A, the distribution of tetherin
delGPI presented as dense punctas with a tendency to spread out-
ward from the perinuclear area. This pattern indicates that the pro-
tein mainly accumulated within the recycling endosome, which is
largely consistent with wild-type tetherin [14]. Furthermore, the
distribution patterns of tetherin delGPI and Vpu partially over-
lapped, indicating a certain degree of co-localization. The tetherin
AGMTM delGPI showed quite a similar pattern, indicating that
replacement of its TM domain may result in loss of sensitivity to
Vpu but not from the gross change in subcellular localization.ariants. (A) Schematic representation of the TM domain containing tetherin mutants
rey zigzag) and dimerized cysteines (dark grey short line) are grayscale-coded. (B)
ted with 1 lg pNL4-3 WT or pNL4-3 delVpu and 50 ng wild-type tetherin or mutant
re detected by Western blot. (C) Dimerization of tetherin mutants. 293T cells were
tions and lysed in sample buffer with or without b-ME before immunoblotting with
Fig. 2. Tetherin delGPI mutant directly interacts with HIV-1 Vpu. (A) Localization of tetherin delGPI mutants and Vpu-cmyc. HeLa cells on coverslips were co-transfected with
Vpu-cmyc and tetherin delGPI or AGMTM delGPI plasmids. Cells were ﬁxed and double stained with a mouse anti-myc antibody (green) and a rabbit anti-HA antibody (red).
Cell nuclei were stained with DAPI. Images were taken under a confocal microscope. No less than 30 cells were observed, and the most representative images were chosen. (B)
Veriﬁcation of Vpu afﬁnity for tetherin delGPI mutant. 293T cells in T-25 ﬂasks were co-transfected with 1 lg VR1012 or Vpu-cmyc together with 2 lg tetherin delGPI or
AGMTM delGPI plasmid. Cells were immunoprecipitated with HA-beads. Cell lysates or precipitates were analyzed by immunoblotting to detect tetherin and Vpu-cmyc. (C)
Effect of delGPI tetherin on Vpu-induced wild-type tetherin degradation. 293T cells were co-transfected with 400 ng Flag-tetherin plasmid, 400 ng Vpu-cmyc plasmid and
400 ng of each tetherin delGPI mutant. Cells were harvested at 48 h for immunoblotting analysis. (D) Effect of delGPI tetherin on Vpu-induced CD4 degradation. 293T cells
were co-transfected with 400 ng CD4-HA plasmid, 400 ng Vpu-cmyc plasmid and 400 ng tetherin delGPI mutants. Cells were harvested at 48 h for immunoblotting analysis.
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Next, the interaction of delGPI tetherin with Vpu was veriﬁed
by immunoprecipitation. 293T cells were co-transfected with the
tetherin delGPI or tetherin AGMTM delGPI plasmid along with
the Vpu-cmyc plasmid. Cells were lysed and incubated with
HA-beads to precipitate HA-tagged tetherin. As shown in Fig. 2B,
expression levels of Vpu in the three samples were comparable,
and those of delGPI and AGMTM delGPI tetherin were similar as
well (pre-immunoprecipitation lysates). Vpu was nearly absent
in the mock control immunoprecipitation sample. Meanwhile,
Vpu was pulled down with tetherin delGPI. However, when tether-
in AGMTM delGPI was precipitated, the Vpu band was much weak-
er than that with tetherin delGPI. This result conﬁrmed that the
tetherin delGPI mutant maintained Vpu binding activity.
3.6. Tetherin delGPI mutant inhibits Vpu-induced degradation of
tetherin and CD4
Down-regulation of tetherin and CD4 are important Vpu func-
tions, both of which involve the decrease of the target protein at
the cell surface and subsequent cellular degradation. Currently,
the tetherin interacting region is considered to be located mainly
in the Vpu TM domain; meanwhile, the cytoplasmic domain of
Vpu are critical for CD4 interaction, although the Vpu TM domain
has also been implicated in this process [26]. We have also
previously shown that mutation in the C-terminal end of the Vpu
TM domain affects Vpu-induced CD4 down-regulation [19]. After
demonstrating the considerable afﬁnity of delGPI tetherin forVpu, we carried out co-transfection experiments in 293T cells to
further validate its inﬂuence on Vpu functions. As shown in
Fig. 2C, delGPI tetherin exhibited no signiﬁcant effect on the level
of wild-type tetherin in the absence of Vpu. In the presence of
Vpu, however, delGPI tetherin drastically altered the Vpu-induced
degradation of wild-type tetherin, while its counterpart AGMTM
delGPI tetherin could not. Unexpectedly, delGPI tetherin also
inhibited CD4 degradation as shown in Fig. 2D, suggesting a con-
siderably potent block directed toward the whole Vpu TM domain.
Another intriguing observation was that delGPI tetherin itself was
resistant to the Vpu-induced degradation even though it could
strongly interact with Vpu.
3.7. Transient expression of tetherin delGPI mutant inhibits HIV-1
virion release in tetherin-positive cells
In order to detect its blocking effect on Vpu, the tetherin delGPI
mutant was co-expressed with a wild-type or Vpu-defective HIV-1
provirus in endogenous tetherin-positive HeLa cells, followed by
assessment of virion release. Relatively high doses of vectors were
used in the transfections. Virions in the supernatants were pelleted
to analyze the p24 capsid protein content, while cells were col-
lected for the detection of Pr55Gag and tubulin. As shown in
Fig. 3A (left panel, wild-type HIV-1; right panel, Vpu-defective
HIV-1), Pr55Gag levels in all samples were equal. Compared to
the release of wild-type virus which was set to 100% (Fig. 3A, lane
1), the release of wild-type virus from cells expressing tetherin del-
GPI decreased to about 1/3 (Fig. 3A, lane 2), while it was essentially
unchanged from cells expressing tetherin AGMTM delGPI (Fig. 3A,
M. Lv et al. / FEBS Letters 587 (2013) 37–43 41lane 3). The two mutants containing the C53,63,91A changes
showed similar inhibitory effects on the wild-type virus (Fig. 3A,
lanes 4 and 5). Meanwhile, the release of Vpu-defective HIV-1
was relatively low (Fig. 3A, lane 6). In the presence of the tetherin
delGPI mutant, the release of Vpu-defective virus was still signiﬁ-
cantly inhibited, but it was moderately higher than that in the
absence of tetherin delGPI mutant (Fig. 3A, lane 7). Of note, levels
of virus release with tetherin delGPI and tetherin AGMTM delGPI
(Fig. 3A, lanes 7 and 8) were even higher than those in the presence
of the two C53,63,91A cysteine mutants (Fig. 3A, lanes 9 and 10).
These observations suggest that overexpression of the TM domain
containing tetherin mutant in tetherin-positive HeLa cells resulted
in considerable inhibition of the release of Vpu-positive HIV-1.
3.8. Transient expression of tetherin delGPI mutant dose-dependently
inhibits infectious HIV-1 release in tetherin-positive cells
To further validate the above results, we carried out a similar but
more elaborate virus release experiment with a range of doses ofFig. 3. Transient expression of tetherin delGPI mutant inhibits HIV-1 release in tetherin-p
wild-type HIV-1 virion release in HeLa cells. HeLa cells were co-transfected with 1 lg pr
48 h. Virus particles in culture supernatants were concentrated by ultracentrifugation an
were examined to exclude variations due to transfection efﬁciency. Equal loading was con
densitometry. (B) Dose-dependent inhibition of infectious wild-type HIV-1 virion releas
proviral plasmids pNL4-3 WT or pNL4-3 delVpu and indicated doses of each tetherin mu
incubation with TZM-bl indicator cells. Cells were lysed and analyzed immediately for
performed in duplicate.tetherin delGPI plasmids. Here we measured virion release with a
high-throughput assay by titration of infectious particles on TZM-
bl indicator cells. The culture supernatants of transfected cells were
collected, ﬁltered and used to infect TZM-bl cells, which were cul-
tured for another 48 h before luciferase activity detection. The lucif-
erase valueswere converted to percentages, and thewild-type virus
release without any tetherin plasmid was set to 100% (Fig. 3B). The
release of wild-type as well as Vpu-defective HIV-1 gradually
decreasedwith increasing amounts of the fully functional wild-type
tetherin used as a positive control (Fig. 3B, a). With gradually
increasing amounts of tetherin delGPI and tetherin delGPI
C-A (Fig. 3B, b and d, hollow points), the release of the
wild-type HIV-1 displayed a similar declining trend as with the
wild-type tetherin; whereas the corresponding AGMTM mutants
showed no signiﬁcant effects on the release of wild-type HIV-1
(Fig. 3B, c and e, hollowpoints). On the other hand, increases of teth-
erin delGPI and tetherin AGMTM delGPI resulted in a moderately
weak increase of the release of Vpu-defective HIV-1 (Fig. 3B, b and
c, solid points), while their corresponding C53,63,91A mutants didositive cells. (A) Overexpression of tetherin delGPI mutant at a single dose inhibited
oviral plasmid pNL4-3 WT or pNL4-3 delVpu and 50 ng of each tetherin mutant for
d analyzed by detection of p24 capsid. Intracellular Pr55Gag proteins in cell lysates
trolled by monitoring tubulin. The level of p24CA in each sample was quantiﬁed by
e in HeLa cells by wild-type or delGPI tetherin. HeLa cells were co-transfected with
tant for 48 h. Equal volumes of culture supernatants were assayed for infectivity by
luciferase activity. All results are representative of two independent experiments
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these dose–response experiments, we saw basically the same trend
as with the above overexpression experiments in that the TM do-
main containing tetherin delGPI mutant could block the interaction
between HIV-1 Vpu and endogenous tetherin with relatively high
efﬁciency.
3.9. Stable delivery of tetherin delGPI mutant inhibits infectious HIV-1
release in tetherin-positive cells
Whether an antiviral molecule can be practically expressed in
sufﬁcient amounts in a clinically relevant context and whether it
exhibits comparable effects in a steady state of expression and in
transient expression are important determinants of success of
the therapeutic strategy. After observing above the potent inhibi-
tion of Vpu by transiently expressed delGPI tetherin protein, teth-
erin-positive HeLa cells and tetherin-negative 293T were used to
stably express delGPI tetherin (with AGMTM delGPI tetherin as a
control) via a lentiviral vector as described in Materials and Meth-
ods. After two weeks of lentivirus infection and antibiotic screen-
ing, cells expressing the protein of interest in a steady state were
obtained and conﬁrmed by Western blotting. The expression pat-
tern of the stable tetherin delGPI protein, similar to endogenous
tetherin, showed more multimeric bands than did the transient
tetherin protein. (Fig. 4A). Additionally, the expression level ofFig. 4. Stable expression of tetherin delGPI mutant inhibits HIV-1 release in
tetherin-positive cells. (A) Single-cycle replication assay in 293T and HeLa cells
stably expressing delGPI tetherin. Cells were infected with equivalent doses of the
indicated VSV-G pseudotyped virus for 48 h. The p24CA levels in released virions
pelleted by ultracentrifugation were analyzed by Western blot, and bands were
quantiﬁed by densitometry. (B) The relative infectious virus yield of (A) was further
determined by incubation with TZM-bl indicator cells. Cells were lysed and
analyzed immediately for luciferase activity. All results are representative of two
independent experiments performed in duplicate.the mutant in 293T cells was slightly higher than that in HeLa cells
(Fig. 4A). The different types of cells were infected with VSV-G
pseudotyped HIV-1. The released virions were evaluated by ultra-
centrifugation, and infectious particles were titrated on TZM-bl
indicator cells. As shown in Fig. 4A and B, nearly the same levels
of wild-type HIV-1 and Vpu-defective viruses were released from
293T cells, and no signiﬁcant difference was observed in the levels
of released virions from the parental 293T cells and 293T cells sta-
bly expressing tetherin mutant. In the parental HeLa cell line, HIV-
1 delVpu was released at a low level, but wild-type HIV-1 was still
released at a high level. Notably, the level of released wild-type
HIV-1 decreased by more than 60% in HeLa cells stably expressing
delGPI tetherin, while no such apparent change was observed in
HeLa cells stably expressing AGMTM delGPI tetherin. In addition,
the stable delGPI and AGMTM delGPI tetherin also showed a very
weak up-regulatory effect on release of Vpu-defective HIV-1.4. Discussion
Further improvements in treatment options would be best ob-
tained by in-depth studies of the virological characteristics and
pathogenic mechanisms of HIV-1 in order to discover new drug tar-
gets. Induction of the tetherin host restriction factor by IFN-a [27] to
enhance its antiviral activity or inhibition of its antagonist HIV-1
Vpu are both potential options for the treatment of HIV-1. However,
due to the involvement of IFNs in many other biological processes,
thenon-speciﬁc IFN-a treatmentmay causemanyside effectswhich
would not render it a particularly feasible therapeutic approach
[28,29]. A functionally complete tetherin TM variant will probably
be a more potent alternative. However, an excess of a functional
antiviral protein is likely to trigger other unknown effects, such as
the heavy selective pressure that may cause the virus to evolve
new a mechanism to antagonize or evade the inhibition. Notably,
the effect of tetherin on HIV-1 has been considered recently to ex-
tendbeyond the inhibitionof virion release (reviewed in [30]). Other
functionsproposed for tetherinhave included theenhancement [31]
or inhibition [32] of cell-to-cell transmission, and even the decrease
of viral infectivity [33]. Although theprecise tetherin functionsespe-
cially in the lymphocytes are still in debate, some of these observed
phenomenamay be attributed to the use of a strong promoter to ex-
press exogenous functional tetherin. Therefore, restoring the func-
tion of endogenous host antiviral factor would be the best
therapeutic weapon, as well as a safer and more effective antiviral
strategy, if inhibiting the viral antagonistic factor could be achieved.
To date, the mechanism of Vpu-mediated antagonism of tether-
in has not been fully deﬁned, making it difﬁcult to ﬁnd methods/
agents to inhibit this viral factor. Amphotericin B methyl ester
(AME) was found to interfere with the HIV-1 budding process in
a Vpu-dependent manner [34], suggesting that it may disrupt the
anti-tetherin function of Vpu. However, the blocking mechanism
of AME against Vpu activity has not been further elaborated.
In conclusion, we have demonstrated that the tetherin delGPI
mutant potently inhibited the release of wild-type HIV-1 from
tetherin-positive HeLa cells, suggesting that this truncated mole-
cule could block and competitively inhibit the interaction of Vpu
with endogenous tetherin through its TM region. Meanwhile, the
tetherin delGPI mutant also caused a moderately weak recovery
of virus release in the absence of Vpu, raising the possibility of
heterologous dimerization between this molecule and endogenous
tetherin. These results support the feasibility of blocking the Vpu/
tetherin interface as a therapeutic target. Speciﬁcally, interrupting
the interaction between HIV-1 Vpu and endogenous tetherin via
gene transfer of tetherin TM helical peptides or small molecule
inhibitors may be a novel and feasible approach for future
treatments aimed at inhibition of HIV-1 release.
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